Narasimhan Mani
About Narasimhan Mani
Narasimhan “Dr.” Mani, age 51, is Co-Chief Executive Officer, President, and a director of Scienture Holdings, Inc. (SCNX) since May 20, 2025 . He is a 25+ year healthcare executive with CEO experience at Kesin Pharma and Xiromed, plus corporate strategy leadership at Amneal; earlier roles included corporate finance at Johnson & Johnson and R&D/product development at Forest Laboratories and Par Pharmaceuticals; degrees include B.Pharm (Hons.) BITS Pilani (1995), M.S. Analytical Chemistry (1998), Ph.D. Pharmaceutics (2003), and MBA Columbia (2008) . Company-level performance context: 2024 Total Shareholder Return (TSR) rose to 102 from 87 in 2023 and net income improved to $13.6 million in 2024 from a $17.8 million loss in 2023 . Mani beneficially owns 2,445,515 SCNX shares, or 7.65% of outstanding, as of October 22, 2025 .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Kesin Pharma Corporation | President & Chief Executive Officer | — | Led commercialization of specialty/brand products |
| Xiromed LLC | Chief Executive Officer | — | Led generics and specialty drug product strategy |
| Amneal Pharmaceuticals | Vice President, Global Corporate Strategy & Business Development | — | Led global strategy, portfolio, BD, commercial operations |
| Johnson & Johnson | Corporate Finance and Strategic Planning Leader | — | Finance and planning across pharma/devices |
| Forest Laboratories | Research Scientist / Product Development | — | R&D contributions in pharmaceuticals |
| Par Pharmaceuticals | Research Scientist / Product Development | — | R&D and product development roles |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| New Rhein Healthcare Investors | Executive-in-Residence | — | Life-sciences focused private equity firm |
| Corsair Pharma, Inc. | Director (Board member) | — | Portfolio company of New Rhein |
Board Governance
- Current board role: Director since May 2025; not independent due to serving as Co-CEO and President .
- Committee membership: None; Audit, Compensation, and Nominating committees are composed exclusively of independent directors (Fell, Doshi, Jayanthi) .
- Board leadership: Chairman is Dr. Shankar Hariharan (also Co-CEO) .
- Board process: In FY 2024, the Board met 13 times; each director attended at least 75% of combined Board and applicable committee meetings; independent directors held 5 executive sessions without management (5 of which included meetings with the independent auditors) .
- Dual-role implications: Mani’s executive-director status reduces independence; checks include committee structures comprised of independent directors .
Director Compensation (Context)
| Name | Fees Earned (Cash) | Stock Awards | Option Awards | All Other Comp | Total |
|---|---|---|---|---|---|
| Narasimhan Mani (Executive Director) | $0 | $0 | $0 | $0 | $0 |
Independent director policy: annual restricted stock grant valued at $55,000, vesting quarterly over a year, and annual cash retainer of $35,000 .
Fixed Compensation
| Component | Pre-10/01/2025 | Effective 10/01/2025 |
|---|---|---|
| Base salary (Scienture LLC employment) | $325,000 | $400,000 |
| Additional compensation for Co-CEO/President roles at SCNX | $0 | $0 |
| Director fees (2024) | $0 | — |
Notes: On October 20, 2025, Scienture LLC executed amendments effective October 1, 2025 increasing Mani’s annual base salary and modifying severance obligations; amendments approved by the Compensation Committee . As employees of Scienture, both Co-CEOs receive no additional compensation for SCNX Co-CEO duties, President role, or employee-director service .
Performance Compensation
- No performance-based bonus targets, weights, or outcomes for Mani were disclosed in the 2025 proxy or 2025 10-Q excerpts reviewed; Compensation Committee charter empowers the committee to set CEO goals/objectives, oversee annual salary/bonus/incentive/equity compensation, and administer equity plans . As employees of Scienture, Mani receives no additional SCNX compensation for Co-CEO/President roles .
Equity Ownership & Alignment
| Metric | Value |
|---|---|
| Shares beneficially owned | 2,445,515 |
| Ownership % of outstanding | 7.65% (based on 31,975,003 shares outstanding) |
| Executive officers and directors as a group | 6,838,699 shares; 21.39% |
| >5% stockholders | None |
| Insider trading policy | Trading windows required; anti-hedging provisions prohibit short sales; 10b5-1 plans allowed with preapproval |
No disclosure identified on pledging of shares by Mani; anti-hedging policy is disclosed, but pledging restrictions are not specifically mentioned in the materials reviewed .
Employment Terms
| Term | Detail |
|---|---|
| Appointment date | Appointed Co-CEO, President, and director on May 20, 2025 |
| Employer entity | Scienture, LLC (wholly owned subsidiary) |
| Latest employment amendment | Effective October 1, 2025; base salary increased to $400,000 |
| Severance | Employment amendment “modifies … severance obligations … in the event of termination without Cause or for Good Reason” (specific multiples/terms not disclosed) |
| Additional SCNX comp for roles | None for Co-CEO, President, or employee-director service |
| Independence status | Not independent (executive-director) |
| Related-party transactions | None; Mani has no direct or indirect material interest requiring Item 404(a) disclosure |
Performance & Track Record (Company Context)
| Year | TSR ($100 initial investment) | Net Income (Loss) ($000s) |
|---|---|---|
| 2023 | 87 | (17,844) |
| 2024 | 102 | 13,632 |
Additional context: SCNX executed an ATM program in September–October 2025 and repaid the Streeterville Note; these capital actions are corporate-level and not executive-compensation outcomes .
Compensation Committee Analysis
- Composition: Independent directors only; Chair Donald G. Fell; members Mayur Doshi and Subbarao Jayanthi .
- Responsibilities: Establish CEO goals/objectives; review/approve executive salary/bonus/incentive/equity; administer equity plans; oversee termination packages; review non-employee director pay; produce annual report on compensation per SEC rules .
- Interlocks: None disclosed; no member was an officer/employee during the fiscal year; no related-party relationships requiring disclosure .
Investment Implications
- Alignment: Mani’s significant ownership stake (7.65%) indicates strong economic alignment; anti-hedging rules reduce misalignment risks from short sales .
- Cash vs. variable mix: The October 2025 employment amendment raises fixed pay to $400k, increasing guaranteed compensation; absence of disclosed performance-based targets/outcomes for Mani limits visibility into pay-for-performance rigor .
- Retention and severance: Severance obligations were modified in October 2025 for termination without cause or for good reason, indicating negotiated retention economics; lack of detail on multiples or triggers constrains modeling of change-of-control costs .
- Governance controls: Dual executive-director status reduces independence, but committees are fully independent with clear charters; Mani receives no additional SCNX compensation for his board/executive roles, mitigating pay stacking concerns .
- Ownership dilution and signals: The 2025 ATM activity and reverse split authorization proposals are capital structure considerations; they are not directly linked to Mani’s personal compensation but may influence equity-based incentives and insider selling windows .
Citations: